Efecto cardioprotector de los inhibidores de sglt2 y agonistas del receptor de glp-1

Resumen

Metodología: Se realizó una revisión narrativa a través de diversas bases de datos de Enero de 2015 a Enero de 2022; la búsqueda y selección de artículos fue llevada a cabo en revistas indexadas en idioma inglés. Se utilizaron como palabras clave: Cardioprotector, inhibidores de SGLT2, agonistas del receptor de GLP-1. Resultados: Los SGLT2i reducen la hemoglobina glicosilada entre un 0,5 % y un 1,0 % demostrando efectos favorables sobre el peso corporal, la presión arterial, el perfil lipídico, la rigidez arterial y la función endotelial. Los análogos del GLP-1 reducen significativamente los valores de la Presión arterial. Los mecanismos fisiológicos por los cuales se llega a una regulación aun no son del todo claras. Se han planteado diversos mecanismos, dentro de los cuales encontramos la activación directa del receptor del GLP-1 en las arterias y el sistema renal, incluida una mejora de la función endotelial, así como un efecto vasodilatador y natriurético. Conclusiones: La presente revisión ofrece información actualizada y detallada sobre los efectos cardioprotectores que son brindados por el uso de los inhibidores de SGLT2 y agonistas del receptor de GLP-1 en pacientes diabéticos, especialmente en aquellos con factores de riesgo de desarrollar enfermedades cardiovasculares.

Palabras clave: cardioprotector, inhibidores de SGLT2, agonistas del receptor de GLP-1

Descargas

La descarga de datos todavía no está disponible.

Citas

R. Salvatore, A. Biagio, C. Eusebio. B. Antonio, I. Ciro, P. Daniela. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front. Endocrinol., 17 January 2018. https://doi.org/10.3389/fendo.2018.00002

M. Benjamin, M. Thomas. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015 Oct 10; 6(13): 1246–1258. doi: 10.4239/wjd.v6.i13.1246

J. Robert. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018 Nov;14(6):491-509. doi: 10.2217/fca-2018-0045.

F. Wnjun. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology: March 2017-Vol6-Issue1-p8-16. doi: 10.1097/XCE.0000000000000116

M. Ann. Diabetes Mellitus and Cardiovascular Disease. Arteriosclerosis, Thrombosis, And Vascular Biology. https://doi.org/10.1161/ATVBAHA.119.310961

C. Bryce, G. Gordon. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes Metab Syndr Obes. 2019; 12: 2125–2136. doi: 10.2147/DMSO.S212003

S: Daniel, G. Owen, T. William. An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus. Curr Opin Endocrinol Diabetes Obes. 2017 Feb; 24(1): 73–79.doi: 10.1097/MED.0000000000000311

P. Lalita, I. Diana. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015; 4: 212283. doi: 10.7573/dic.212283

M. Jennifer, N. Wesley, A. Brooke. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021 Mar 9;12:2042018821997320. doi: 10.1177/2042018821997320

T. Anastasios, V. Panayotis, T. Evangelia. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int J Environ Res Public Health. 2019 Aug 17;16(16):2965. doi: 10.3390/ijerph16162965.

D. Theodosios, L. Angelos, P. Ioanna. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019 Mar;131(2):82-88. doi: 10.1080/00325481.2019.1581971.

T. Maximilian, R. Johannes, W. Stefan. Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na +?. Int J Mol Sci. 2021 Jul 26;22(15):7976. doi: 10.3390/ijms22157976.

N. Maja, Z. Vladimir. J. Jovana. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Fail Rev. 2021 Feb 3. doi: 10.1007/s10741-021-10079-9.

R. Asadur, H. Hirofumi, N. Akira. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertens Res. 2017 Jun;40(6):535-540. doi: 10.1038/hr.2016.193.

M. Chang, C. Sungsoo, Y. Ji, K. Hyeongseok. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure. Korean Circ J. 2019 Dec;49(12):1183-1195. doi: 10.4070/kcj.2019.0180.

S. Danubia, Z. Juliano, A. Flavio. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C328-C336. doi: 10.1152/ajpcell.00275.2019.

D. Gary, V. Subodh. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors. JACC Basic Transl Sci. 2020 Jun; 5(6): 632–644. doi: 10.1016/j.jacbts.2020.02.004

O. Chang-Myung, C. Sungsoo, J. Ji-Yong. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure. Korean Circ J. 2019 Dec; 49(12): 1183–1195. doi: 10.4070/kcj.2019.0180

K. Keshac, B. Tapan, K. Arun, A. Sandeep. SGLT-2 Inhibitors: Ideal Remedy for Cardioprotection in Diabetes Mellitus. Curr Mol Pharmacol. 2021 Oct 25;14(4):487-497. doi: 10.2174/1874467213666201012161439.

P. Giuseppe, C. Arturo, V. Erica, P. Pia, G. Raffaele. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int J Mol Sci. 2021 May 30;22(11):5863. doi: 10.3390/ijms22115863.

P. Milton. Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors. Circ Heart Fail. 2020 Sep;13(9):e007197. doi: 10.1161/CIRCHEARTFAILURE.120.007197.

D. Gary, V. Subodh. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. doi: 10.1016/j.jacbts.2020.02.004.

L. Sarayut, C. Siriporn, C. Nipon. Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 2018; 17: 101. doi: 10.1186/s12933-018-0745-5.

K. Dimos, C. David, S. DImitrios, T. Aphrodite. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure. Curr Pharm Des. 2021;27(8):1051-1060. doi: 10.2174/1381612826666201103122813.

O. Utkarsh, R. Lenisse, E. Florence. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. Am J Cardiovasc Drugs. 2022 Jan;22(1):35-46. doi: 10.1007/s40256-021-00486-6.

C. Frank, O. Per. Cardioprotection with Yet Another SGLT2 Inhibitor - An Embarrassment of Riches. N Engl J Med. 2021 Jan 14;384(2):179-181. doi: 10.1056/NEJMe2033176.

U. Saad, R. Faiga. Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus. Cureus. 2020 Aug; 12(8): e9655. doi: 10.7759/cureus.9655.

J. Maria, W. Jan. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019 Feb;79(3):219-230. doi: 10.1007/s40265-019-1057-0.

M. Colleen, L. George. Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes. Diabetes Care, Vol 38, Issue 3, 1 March 2015. https://doi.org/10.2337/dc14-1596.

S. Zsolt, T. Kalman, S. Eszter. The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites. 2021 Feb 1;11(2):87. doi: 10.3390/metabo11020087.

B. Agnes, O. Christian, J. Susanne. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019; 18: 44. doi: 10.1186/s12933-019-0839-8.

D. William, B. Ghazaleh, J. Kelly. Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling. Int J Mol Sci. 2021 Aug; 22(16): 8786. doi: 10.3390/ijms22168786.

M. Sunder. Integrating cardioprotective glucose-lowering medications into clinical practice. Cardiovasc Endocrinol Metab. 2018 Mar; 7(1): 24–27. doi: 10.1097/XCE.0000000000000142

T. Juan. Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. Eur Cardiol. 2019 Apr; 14(1): 23–32. doi: 10.15420/ecr.2018.34.2

G. Angus, P. Stephen, A. Karin, M. Anna. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. Curr Diabetes Rev. 2019;15(5):349-356. doi: 10.2174/1573399814666180417121246.

N. Yasuaki, K. Koichiro. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. J Cardiol. 2020 Aug;76(2):123-131. doi: 10.1016/j.jjcc.2020.03.009.

T. Pongpan, S. Piangkwan, S. Sivaporn. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. 2018 Feb;236(2):69-84. doi: 10.1530/JOE-17-0457.

R. Lars, F. Giulia, M. Linda. Is cardioprotection with GLP-1 receptor agonists a class effect?. European Journal of Preventive Cardiology, Volume 28, Issue 1, January 2021. https://doi.org/10.1093/eurjpc/zwaa103

A. Asim, A. Noora, Y. Israa. Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review. Curr Diabetes Rev. 2020;16(8):820-832. doi: 10.2174/1573399816666200522214554.

I. Maria, J. Juan. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res. 2018; 2018: 4020492. doi: 10.1155/2018/4020492

G. Dario, S. Lorenzo, L. Miriam. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology. 15 september 2021

A. Eirini, T. Costas, A. Ioannis, L. Ioannis. GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic Journal of Cardiology. Volume 60, Issue 6, November–December 2019, Pages 347-351. https://doi.org/10.1016/j.hjc.2018.11.008.

M. Ahsan, M. Dhanwantee, B. Sanja. M. Abdul. Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α. The Journal of Clinical Investigation. January 27, 2020. Doi: 10.1172/JCI99934

J. Kai, W. Dandan, C. Feng, T. Zizhuo. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2021 Jan 8. doi: 10.1007/s13238-020-00809-4.

R. Sahithi, H. Tinaz, H. Hanan, A. Mahmoud. Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review. Cureus. 2021 Sep; 13(9): e17668. doi: 10.7759/cureus.17668

Publicado
2022-08-29
Cómo citar
Negrete Levette, J. A., Villabona Leal, F. J., Rojas Daza, O. P., Cuellar Anturi, Y., Torres Hernandez, F. A., Benegas Masi, A. J., Ortiz Perez, D. F., Bonfante Villalobos, R. J., & Plata Mora, J. F. (2022). Efecto cardioprotector de los inhibidores de sglt2 y agonistas del receptor de glp-1. Ciencia Latina Revista Científica Multidisciplinar, 6(4), 2497-2511. https://doi.org/10.37811/cl_rcm.v6i4.2776
Sección
Artículos

Artículos más leídos del mismo autor/a